Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 3:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 57 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cervical Cancer Cin Grade Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix

NCT00285207
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
Interventions
placebo, A007
Drug
Lead sponsor
Tigris Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2010 · Synced Sep 30, 2026, 3:02 PM EDT
Completed Phase 2 Interventional

A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection

NCT01022346
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
Placebo, RO5217790
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
43
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Sep 30, 2026, 3:02 PM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors

NCT00001073
View directory record Official record
Conditions
HIV Infections, Cervix, Dysplasia
Interventions
Isotretinoin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 30, 2026, 3:02 PM EDT
Terminated Phase 1 Interventional

Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia

NCT00005808
View directory record Official record
Conditions
Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 2, Cervical Intraepithelial Neoplasia Grade 3
Interventions
motexafin lutetium, photodynamic therapy, loop electrosurgical excision procedure, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Sep 30, 2026, 3:02 PM EDT
Not listed Phase 2 Interventional

Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL

NCT02576561
View directory record Official record
Conditions
Human Papillomavirus, High-Grade Squamous Intraepithelial Lesions
Interventions
TVGV-1, GPI-0100, Placebo
Biological
Lead sponsor
THEVAX Genetics Vaccine
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Tucson, Arizona • Lakewood, Colorado • Port Orange, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 30, 2026, 3:02 PM EDT
Recruiting Phase 2 Interventional

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

NCT04712851
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2
Interventions
Pembrolizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 30, 2026, 3:02 PM EDT
Completed Phase 1 Interventional

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection

NCT03239223
View directory record Official record
Conditions
HSIL, HSIL of Cervix, High-Grade Squamous Intraepithelial Lesions, High-grade Cervical Intraepithelial Neoplasia, Human Papilloma Virus, Cervical Cancer, Cervical Intraepithelial Neoplasia, Cervical Neoplasm, Cervical Dysplasia, CIN
Interventions
ABI-1968
Drug
Lead sponsor
Antiva Biosciences
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Los Angeles, California • Lake Worth, Florida • Idaho Falls, Idaho + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Sep 30, 2026, 3:02 PM EDT
Completed No phase listed Observational

IMproved PRactice Outcomes and Value Excellence in Colposcopy

NCT02185599
View directory record Official record
Conditions
High Grade Cervical Intraepithelial Neoplasia
Interventions
DySIS
Device
Lead sponsor
DySIS Medical Inc.
Industry
Eligibility
21 Years and older · Female only
Enrollment
7,555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
46
States / cities
Scottsdale, Arizona • Gainesville, Florida • Jacksonville, Florida + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Sep 30, 2026, 3:02 PM EDT
Withdrawn Phase 2 Interventional

A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia

NCT01925378
View directory record Official record
Conditions
Cervical Dysplasia
Interventions
Nelfinavir
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 30, 2026, 3:02 PM EDT
Terminated Phase 2 Interventional

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00312286
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
851B
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
88
States / cities
Birmingham, Alabama • Enterprise, Alabama • Huntsville, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Sep 30, 2026, 3:02 PM EDT
Completed Phase 2 Interventional

Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

NCT00006079
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Eflornithine, Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Sep 30, 2026, 3:02 PM EDT
Completed Not applicable Interventional

UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia

NCT00003598
View directory record Official record
Conditions
Cervical Cancer, Precancerous/Nonmalignant Condition
Interventions
tretinoin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
14 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 22, 2010 · Synced Sep 30, 2026, 3:02 PM EDT
Recruiting Phase 1 Interventional

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma

NCT06191133
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Invasive Cervical Cancer
Interventions
Fenofibrate, Cervical Conization, Hysterectomy, Chemoradiation
Drug · Procedure · Radiation
Lead sponsor
Lindsay Ferguson, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 30, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

NCT03185013
View directory record Official record
Conditions
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions
VGX-3100, Placebo, Electroporation (EP)
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
22
States / cities
Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 30, 2026, 3:02 PM EDT
Terminated Phase 2 Interventional

Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL

NCT03911076
View directory record Official record
Conditions
ASC-US, ASC-H, LSIL
Interventions
PVX-2, Placebo
Biological · Other
Lead sponsor
PapiVax Biotech, Inc.
Other
Eligibility
25 Years to 70 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Port Saint Lucie, Florida • Newark, New Jersey • Fairfield, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 30, 2026, 3:02 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

NCT00054041
View directory record Official record
Conditions
Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 3, Human Papilloma Virus Infection
Interventions
HspE7, therapeutic conventional surgery, laboratory biomarker analysis
Biological · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
17 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Sep 30, 2026, 3:02 PM EDT
Withdrawn Phase 1 Interventional

E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia

NCT04411134
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
E7 TCR
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Sep 30, 2026, 3:02 PM EDT
Completed Phase 2 Interventional

Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia

NCT00031759
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
imiquimod, Ablative or excisional therapy
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 30, 2026, 3:02 PM EDT
Terminated Phase 2 Interventional Results available

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

NCT03267680
View directory record Official record
Conditions
Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion
Interventions
Cyclophosphamide, Indomethacin, IRX-2, Laboratory Biomarker Analysis, Multivitamin, Omeprazole, Placebo, Therapeutic Conventional Surgery
Drug · Biological · Other + 2 more
Lead sponsor
University of Southern California
Other
Eligibility
25 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Sep 30, 2026, 3:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

NCT00121173
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Sep 30, 2026, 3:02 PM EDT
Completed Phase 1 Interventional Results available

Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)

NCT00988559
View directory record Official record
Conditions
HPV16 Positive, Cervical Intraepithelial Neoplasia (CIN 2/3)
Interventions
DNA vaccination, Gene gun vaccine, intramuscular vaccination, intra-lesional vaccine administration, therapeutic resection of the lesion, imiquimod
Biological · Device · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 30, 2026, 3:02 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia

NCT00788164
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition, HPV Disease, Human Papilomavirus
Interventions
TA-HPV, pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine, imiquimod
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Sep 30, 2026, 3:02 PM EDT
Completed Phase 2 Interventional

A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)

NCT00596258
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
Interventions
A-007
Drug
Lead sponsor
Tigris Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Tucson, Arizona • Costa Mesa, California • Boynton Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2009 · Synced Sep 30, 2026, 3:02 PM EDT
Completed Phase 1 Interventional Results available

Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

NCT02354534
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia Grade 2/3, High-risk HPV (Any Strain)
Interventions
Artesunate Suppositories
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Baltimore, Maryland • Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Sep 30, 2026, 3:02 PM EDT